: iStockAnalyst.com Symbols Feed

Analyst Comments: Enzon Pharma, BHP Billiton, Lincoln Electric, Hologic, Ardea Biosciences, Gafisa, Buckeye Partners, Take-Two

Mon, 18 Aug 2008 18:50:00 GMT

Enzon Pharmaceuticals? (ENZN) key product Abelcet, a treatment for fungal infections, sales continued to deteriorate in 2008. Further, another major source of revenue, Royalty, is also under pressure from competition. However, sales in two other products, Oncaspar (for acute lymphoblastic leukemia) and Adagen (for severe combined immunodeficiency disease) are picking up momentum and offsetting the sales decline from Abelcet and Royalty. We are impressed with strong sales growth of Oncaspar. We expect total revenue to remain stable or experience modest growth in the coming years while the company is progressing well with its clinical developments. Enzon is also advancing its pipeline to drive long-term growth. We maintain our Hold rating on the shares. We see a balanced risk/reward profile for Enzon. In our view, there are limited near-term catalysts to[More...]

Analyst Comments: Hospira, Ardea Biosciences, PepsiCo, ZION Bancorp, Procter & Gamble, Beacon Roofing, Amylin Pharmaceuticals, Double Eagle

Tue, 25 Mar 2008 22:34:12 GMT

Hospira, Inc. (HSP) reported Q4 EPS that beat our estimate by $0.07 on sales that significantly exceeded our forecast. We lowered our FY08 sales estimate to within the initial guidance but increased our FY08 EPS estimate.[More...]

Analyst Comments: Zumiez, LSI Corporation, Chunghwa, Kinder Morgan Energy Partners, Kirkland

Mon, 03 Dec 2007 18:10:51 GMT

After hitting an all-time high in October the share price of teen specialty retailer Zumiez, Inc. (ZUMZ), has declined 47%, but Zacks senior retail sector analyst Robert Plaza, CFA still finds them attractive enough to rate them a Buy. The following excerpts explain his position:'Zumiez reported in-line results for the third quarter. The company also issued fourth quarter EPS guidance of $0.48-$0.49 and maintained...[More...]

Gout cases increasing in United States

Sat, 13 Jun 2009 18:36:00 GMT

Gout cases increasing in United States[More...]

Ardea Biosciences Reports Recent Accomplishments and Announces Second Quarter and Year-to-Date 2009 Financial Results

Fri, 07 Aug 2009 12:27:00 GMT

Ardea Biosciences, Inc. (Nasdaq:RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer, inflammatory diseases and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2009.[More...]

Ardea Biosciences Initiates Phase 2b Clinical Trial of RDEA594, Lead Product Candidate for the Treatment of Gout

Mon, 20 Jul 2009 12:09:00 GMT

Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced that it has initiated a Phase 2b clinical trial of RDEA594, its lead product candidate in development for the management of hyperuricemia and gout. The Company also announced the selection of RDEA684, a next-generation URAT1 inhibitor, as a development candidate for the same indication.[More...]

Ardea Biosciences to Present at the 4th Annual Piper Jaffray Europe Conference

Thu, 18 Jun 2009 12:31:00 GMT

Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, Ardea’s president and chief executive officer, will present at the 4th Annual Piper Jaffray Europe Conference.[More...]

Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594

Thu, 11 Jun 2009 11:55:00 GMT

Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced positive interim results from an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results from completed Phase 1 studies of RDEA594 in normal, healthy volunteers. The Phase 1 results, along with additional preclinical data, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.[More...]

Ardea Biosciences to Present Preclinical and Phase 1 Data on its Lead Gout Product Candidate, RDEA594, at the Annual European Congress of Rheumatology

Mon, 18 May 2009 12:46:00 GMT

Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it will present data from multiple Phase 1 studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.[More...]

Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. Urge the Shareholders of Penwest Pharmaceuticals Co. To Vote for Their Shareholder Proposals

Fri, 15 May 2009 14:09:00 GMT

Tang Capital Partners, LP ("Tang Capital") and Perceptive Life Sciences Master Fund Ltd. ("Perceptive") today announced that they have sent a letter to the shareholders of Penwest Pharmaceuticals Co. (NASDAQ: PPCO) ("Penwest" or the "Company").
The letter urges shareholders to vote for shareholder proposals brought by Tang Capital and Perceptive, including proposals to elect three nominees to Penwest's board of directors, amend the bylaws of Penwest and approve a shareholder resolution on the future direction of the Company.
TANG CAPITAL PARTNERS, LP 4401 EASTGATE MALL SAN DIEGO, CA 92121

[More...]

Ardea Biosciences Reports Recent Accomplishments and First Quarter 2009 Financial Results

Fri, 08 May 2009 13:51:00 GMT

Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer and inflammatory diseases, today reported recent accomplishments and financial results for the first quarter ended March 31, 2009 and announced a restructuring of operations.
"Ardea is off to an excellent start in 2009.
Since our last quarterly update, we have reported positive clinical trial results for RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, and announced a global agreement with Bayer HealthCare focused on the development and commercialization of small-molecule, mitogen-activated ERK kinase inhibitors for the treatment of cancer," commented Barry D. Quart, PharmD, Ardea's president and chief executive officer.

[More...]

Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer

Tue, 28 Apr 2009 12:39:00 GMT

Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced that it has entered into a global agreement with Bayer HealthCare focused on the development of small molecule mitogen-activated ERK kinase (MEK) inhibitors for the treatment of cancer. The lead compound in this program, RDEA119, is currently being evaluated in advanced cancer patients as a single agent in a Phase 1 study and in a Phase 1/2 study in combination with sorafenib (Nexavar®, Onyx Pharmaceuticals, Bayer HealthCare).[More...]

Ardea Biosciences Announces Positive Results from a Phase 1 Study of Lead Hyperuricemia and Gout Candidate, RDEA594 and a Phase 2a Study of RDEA594’s Prodrug, RDEA806

Mon, 20 Apr 2009 19:59:00 GMT

Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced positive results from a Phase 1 study in normal, healthy volunteers of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and a pilot Phase 2a proof-of-concept study in gout patients of RDEA594’s prodrug, RDEA806 (RDEA806 is converted to RDEA594 in the body). RDEA594 is an inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion. These data, as well as future development plans for RDEA594, are being presented today at an investor and analyst event hosted by the Company in New York, NY. The Company intends to present further data from RDEA594 studies at an upcoming scientific conference.[More...]

Ardea Biosciences Announces Investor and Analyst Event Participants and Webcast Information

Mon, 13 Apr 2009 12:32:00 GMT

Ardea Biosciences, Inc. (Nasdaq:RDEA), a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer and inflammatory diseases, today announced event participants and webcast information for its Investor and Analyst Event on Monday, April 20, 2009 from 5:00 p.m. to 7:00 p.m. Eastern Daylight Time in New York City.[More...]